The mechanistic basis of gliogenesis, which occurs late in human development, is poorly understood. Here we identify nuclear factor IA (NFIA) as a molecular switch inducing human glial competency. Transient expression of NFIA is sufficient to trigger glial competency of human pluripotent stem cell-derived neural stem cells within 5 days and to convert these cells into astrocytes in the presence of glial-promoting factors, as compared to 3-6 months using current protocols. NFIA-induced astrocytes promote synaptogenesis, exhibit neuroprotective properties, display calcium transients in response to appropriate stimuli and engraft in the adult mouse brain. Differentiation involves rapid but reversible chromatin remodeling, glial fibrillary acidic protein (GFAP) promoter demethylation and a striking lengthening of the G1 cell cycle phase. Genetic or pharmacological manipulation of G1 length partially mimics NFIA function. We used the approach to generate astrocytes with region-specific or reactive features. Our study defines key mechanisms of the gliogenic switch and enables the rapid production of human astrocytes for disease modeling and regenerative medicine.
To monitor the period when astrocytes develop during hPSC differentiation, we generated a knock-in reporter line targeting the aquaporin-4 (AQP4) locus with a nuclear green fluorescent protein (H2B-GFP) ( Supplementary Fig. 1 ). Previous strategies for generating astrocytes from hPSCs include the exposure of factors such as LIF, CNTF, BMP or serum to NSCs to trigger glial differentiation 10, 11 . The onset of glial differentiation was moderately accelerated in NSCs treated with serum ( Supplementary Fig. 2 ), and we tested whether such acceleration was correlated with changes in the expression of candidate factors including NFIA (Fig. 1a ) previously implicated in glial fate acquistion [12] [13] [14] [15] [16] .
To directly test whether these genes impact glial competency or differentiation, we used a homogeneous and stable neurogenic NSC population termed long-term human embryonic stem cell-derived neural stem cells (lt-hESNSCs 17 , referred to as LTNSCs in this study). Unlike NSCs, LTNSCs do not spontaneously undergo the gliogenic switch following long-term culture but remain in the neurogenic phase 18 (Supplementary Fig. 3 ), making them ideal for identifying factors involved in the gliogenic switch. While knockdown of LIN28B did not show any obvious effect, overexpression of NFIA profoundly altered LTNSC morphology ( Supplementary Fig. 4a ,c) and correlated with expression of NFIA protein and CD44 19 , a marker of glial competency, although it did not result in GFAPpositive cells (Fig. 1b) . A subset of NFIA-expressing cells activated the AQP4-H2B-GFP reporter ( Supplementary Fig. 4b ). We hypothesized that overexpression of NFIA would trigger glial competency but block differentiation toward astrocytes. We performed a time course study in which LTNSCs were cultured in the presence (dox+) or absence (dox-) of NFIA expression. After 5 days, cells were switched to (dox-) either in a glial-promoting condition (+LIF) or in NSC maintenance medium (+epidermal growth factor/fibroblast growth factor 2 (EGF/FGF2)). Notably, continued expression of NFIA (dox+) prevented LTNSCs from expressing GFAP even in the presence of LIF ( Fig. 1c (dox+) ). In contrast, removal of doxycycline led to a decline in NFIA expression for both conditions, but GFAP expression was strongly induced only in the (+LIF) group and only after NFIA was sufficiently downregulated (Fig. 1c ). We found that LIF was most efficient in generating GFAP-positive cells and in activating the AQP4-H2B-GFP reporter compared to other glial differentiation factors ( Supplementary Fig. 5a,b) . These results show that glial competency in neurogenic human NSCs can be achieved at as early as 5 days by transient expression of NFIA, compared with 90-180 days using current protocols ( Supplementary Fig. 6a ).
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We determined the timing and efficiency of astrocyte generation using NFIA. While there was a robust increase in GFAP expression, not all cells were immediately immunoreactive to GFAP.
We used intracellular fluorescent activated cell sorter to determine the absolute numbers of GFAP-positive and CD44-positive cells at different passages after NFIA induction ( Supplementary Fig. 6b ). 
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We achieved >60% GFAP-expressing cells by 56 days of culture (d56) and nearly 100% GFAP-positive cells after 77 days (d77) ( Fig. 1d,e ). We determined that the success of astrocyte generation was dependent on the transduction efficiency of the NFIA virus in NSCs. To further improve the efficiency of generating astrocytes from hPSCs ( Supplementary Fig. 6c ), we generated an inducible NFIA hPSC-line (NFIA-hPSC, Supplementary Fig. 7a ). NFIA is not expressed in hPSCs and was induced by dox treatment to identify properly targeted clones ( Supplementary Fig. 7b ). Immunoblot analysis showed that NFIA levels were higher in the inducible line compared to transduced LTNSCs ( Supplementary Fig. 7c ).
To determine efficiency, we differentiated the inducible NFIA-hPSCs into cortical NSCs ( Supplementary Fig. 6c ) and induced NFIA for 10 days ( Supplementary Fig. 7d,e ). Over this time period, 65% of cells became CD44 positive. LIF treatment for 15 days led to 42% of cells expressing GFAP ( Supplementary Fig. 7f -h). Immunostaining of the resulting cells showed expression of S100β and GFAP and loss of the proliferation marker KI-67 ( Supplementary Fig. 7i ). Finally, to test the suitability of the protocol for disease modeling, we differentiated isogenic control and patient-specific iPSCs harboring a mutation in the SOD1 gene (A4V) 20 toward cortical versus spinal cord progenitor identity 18, 21 and confirmed their distinct antero-posterior marker expression ( Supplementary Fig. 8a,b ). By infecting the progenitors with NFIA, we observed the expression of GFAP-positive cells by 6-7 days of differentiation ( Supplementary  Fig. 8c ) resulting in regionally distinct astrocytes ( Supplementary  Fig. 8d ). This reaffirms that NFIA induction is a robust strategy for generation of astrocytes of specific regional identity across control and disease hPSCs.
The cells derived from NFIA-induced NSCs yielded astrocytes with complex morphology (Fig. 1f ) that expressed a panel of genes representing astrocyte identity ( Fig. 1g ). To further determine whether NFIA-induced astrocytes matched those observed in vivo, we performed gene expression profiling ( Fig. 1h) . A broad set of RNA-sequencing data from NFIA-induced astrocytes at various stages of differentiation was compared to published datasets from hPSC-derived astrocytes from conventional, protracted differentiation conditions 6 , hPSC-derived astrocytes from serum exposure 10 and those from primary human fetal tissue 22 . Initial comparison of the samples demonstrated high correlation between the NFIAinduced astrocytes and those generated using protracted methods. This is in contrast to hPSC-derived astrocytes using a serum-based method of differentiation ( Supplementary Fig. 9a,b ). We performed a comparative analysis of our dataset with one that encompasses freshly isolated fetal and adult astrocytes as well as a range of additional primary lineages isolated from human cortex 2 and across a set of astrocyte-specific genes shared among three independent astrocyte studies [23] [24] [25] . This analysis showed close correlation between NFIA-induced astrocytes and fetal astrocytes ( Fig. 1h , Supplementary Fig. 9c,d and Supplementary Table 1 ).
We examined the functionality of NFIA-induced astrocytes. Astrocytes play critical roles during central nervous system development, including neuronal maturation 26 , maintenance of metabolic homeostasis and regulation of inflammation 27 . Several genes associated with the formation of functional synapses 28 were upregulated ( Supplementary Fig. 9e ), suggesting that these cells exhibit functional properties in neuronal maturation. Immature neurons co-cultured in the presence of NFIA-induced astrocytes showed evidence of accelerated maturation by the increased expression and appearance of punctate SYN1 (synapsin-I) ( Fig. 2a ) and upregulation of an active zone marker MUNC13.1 29 (Fig. 2b) . Additionally, the co-localization of pre-and postsynaptic markers, such as SYN1 and HOMER, indicated the formation of structural synapses ( Fig. 2c and Supplementary Fig. 10 ). NFIA-induced astrocytes also promoted neuronal survival when subjected to glutamate excitotoxicity ( Supplementary Fig. 11 ) 30 . Notably, following cytokine treatment, we could trigger the upregulation of reactive astrocyte (A1)-specific transcripts ( Supplementary Fig. 12a ,b) and complement (C3) secretion 1, 31 (Fig. 2d ). Morphologically, astrocytes cultured in different passages appeared to transition from large flat cells to cells with long and complex processes ( Supplementary Fig. 13a ).
NFIA-induced astrocytes can be stimulated to elicit calcium transients 32 in response to specific stimuli. Commercially available primary astrocytes isolated from human fetal brains (19-23 postconception weeks) displayed morphology similar to NFIA-induced astrocytes; however, only a few cells responded to the stimuli ( Supplementary Fig. 14g ). In contrast, NFIA-induced astrocytes responded robustly to KCl and ATP ( Fig. 2e and Supplementary  Fig. 14a-d ) with increasing ATP responsiveness over time ( Supplementary Fig. 14h ). When in co-culture with hPSC-derived neurons, NFIA-induced astrocytes adopted a more ramified appearance ( Supplementary Fig. 13b ), showed increased AQP4-H2B-GFP signal ( Supplementary Fig. 14f ) and the response to ATP increased twofold ( Fig. 2g ). In addition, the magnitude of the glutamate response was enhanced, suggesting a synergistic interaction between the two cell types in mutually driving both glial and neuronal maturation ( Fig. 2f ,g).
We tested whether NFIA-induced astrocytes would promote the functional maturation of immature hPSC-derived cortical neurons ( Supplementary Fig. 15a ). Whole-cell recordings from cortical neurons and cortical neurons cultured with NFIA-induced astrocytes revealed a resting membrane potential of −56.1 ± 2.5 and −72 ± 2.2 mV, respectively ( Fig. 2h) . Similarly, the input resistance of cortical neurons significantly decreased following co-culture with NFIA-induced astrocytes, further suggesting a more mature phenotype in the presence of astrocytes ( Fig. 2i ). To monitor the impact on synaptic maturation, we recorded basal spontaneous miniature excitatory postsynaptic currents (mEPSCs) ( Supplementary Fig. 15b ) and observed a decrease in inter-event interval ( Supplementary  Fig. 15c ) and an increase in mEPSC frequency from 0.22 ± 0.01 to 0.39 ± 0.02 Hz (Fig. 2j ) in neurons co-cultured with glia, indicating increased synaptic activity. We also observed an increase in amplitude (12.5 ± 0.2 versus 13.6 ± 0.2 pA) ( Fig. 2k ) and time course of decay (6.7 ± 0.3 versus 7.6 ± 0.3 ms) ( Supplementary Fig. 15d ) in mEPSCs from neurons in the presence of glia.
Finally, we transplanted neurogenic NSCs, NFIA-induced glialcompetent NSCs or astrocytes in the adult mouse cortex and corpus callosum. At 2 weeks post-transplantation, the glial progenitors migrated extensively from the graft core along white matter tracts ( Fig. 2l ) whereas neurogenic NSCs resulted in a dense graft composed largely of neurons ( Supplementary Fig. 16a -c). The grafted NFIA-induced cells maintained expression of both AQP4-H2B-GFP and GFAP, and displayed morphological features characteristic of human astrocytes by 6 weeks post-transplantation ( Fig. 2m and Supplementary Fig. 16d -f), with complex morphologies and extensive GFAP-positive projections spanning multiple cortical regions 33 ( Supplementary Fig. 16g ).
The above in vitro and in vivo data demonstrate that transient NFIA expression generates functional, region-specific human astrocytes on demand at high speed and with efficiency. Furthermore, they show that NFIA is a key component of the molecular switch for triggering human glial competency. To explore the NFIA mechanism of action, we returned to our initial observation that transient NFIA expression triggers glial competency but does not induce endogenous NFIA expression (refer to Fig. 1c ). Once doxycycline is removed and cells are maintained in NSC media, they lose glial competency ( Fig. 3a ) and return to a neurogenic state ( Fig. 3b ). We performed a time course analysis of ectopic NFIA expression followed by sorting for CD44-positive cells and replating in the absence of dox (dox-) ( Fig. 3c ). We confirmed that NFIA expression is lost after 3 days of culture without doxycycline (d9) (Fig. 3d ). Based on gene expression data by RNA sequencing, we observed . c, Bar chart representing the quantification of SYN1 and HOMER1 puncta on TUJ1-positive neurons (n = 8 biologically independent experiments, mean values are represented in the bar graph) cultured with or without astrocytes for 28 days. One-way ANOVA *(P < 0.05), **(P < 0.01), ****(P < 0.001). d, Bar chart representing the amount of complement (C3) released from NFIAinduced or primary astrocytes treated with IL1α, tumor necrosis factor and C1q for 24 h (n = 3 biologically independent experiments, mean values are presented in bar graph). e, Ratiometric plots of purified NFIA-induced astrocytes (60 days) incubated with the Fura-2 calcium dye and stimulated with adenosine triphosphate (ATP), potassium chlorate (KCl) and glutamate. All data points are plotted as a heatmap below. f, Ratiometric plots of NFIAinduced astrocytes co-cultured with neurons incubated with Fura-2 calcium dye and stimulated with ATP, KCl and glutamate. Ratios were calculated on GFP-positive nuclei. All data points are plotted as a heatmap below. g, Quantification of the number of astrocytes responding to ATP, KCl or glutamate from data presented in e,f and Supplementary Fig. 13 . h, Quantification of resting membrane potential. Student's t-test P = 0.0000186, n = 23, 39. i, Quantification of mean input resistance. Student's t-test P = 0.010, n = 10, 8. j, Mean frequency of neurons with or without astrocytes. Mann-Whitney rank sum P = 0.000155. k, Cumulative distribution of all mEPSC amplitudes recorded. For control neurons 341 mEPSCs were recorded from ten neurons and, for neurons in the presence of glia, 629 mEPSCs were recorded from six neurons. All electrophysiology was performed on three biologically independent experiments. l, Immunofluorescence of NFIA-induced glial progenitors transplanted into mouse cortex depicts migration through the corpus callosum (n = 3 biologically independent animals). Scale bar, 50 μm. m, Immunofluorescence of NFIA-induced astrocytes demonstrates co-expression of AQP4-H2B-GFP, GFAP and the human-specific marker SC-121 (n = 3 biologically independent animals). Scale bar, 10 μm.
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Nature BiotechNology three major clusters among the samples throughout the time course ( Fig. 3e and Supplementary Table 2 ). Of these, neuroepithelialstage NSCs, LTNSCs (d0) and samples reverted to dox-clustered together, supporting the notion that the NFIA pulse cannot maintain glial competency following NFIA withdrawal. Notably, NFIA expression for 6 days induced a chromatin accessibility landscape similar to that of hPSC-derived astrocytes (d200) or glial-competent NSCs (d80) (Fig. 3f ). Differential chromatin accessibility was associated with a clear shift in the enrichment of transcription factor-binding motifs. SOX and ZNF354C motifs were enriched in the d0 (dox-) and the d12 (reverse) conditions, and AP-1, NFIX and NFI half-site motifs were highly enriched in the d6 (dox+) and astrocyte conditions ( Supplementary Fig. 17 ). Unexpectedly, the GFAP promoter did not show differential Fig. 3 | NFIA cannot maintain the glial-competent state. a, FACS plot of CD44-expressing cells treated with continuous doxycycline, or doxycycline removed, demonstrates that CD44 expression is lost after doxycycline removal. b, Immunofluorescence staining for NFIA, GFAP and TUBB3 in NSCs, NFIA-induced NSCs and NFIA-induced NSCs with doxycycline removal (n = 3 biologically independent experiments). c, Schematic representation of cells induced with NFIA and attaining glial competency followed by reversal to glial incompetency with doxycycline withdrawal. d, Quantitative PCR data of NFIA expression. e, Sample distance plot for RNA expression of NSCs at different timepoints related C. f, Sample distance plot for chromatin accessibility compared to glial-competent NSCs (gcNSCs) and hPSC-derived astrocytes (200 days of in vitro culture). g, Example assay for transposase-accessible chromatin using sequencing (ATAC-seq) tracks at the GFAP locus depicting the lack of chromatin accessibility in several NSC samples. h, Bisulfite sequencing of the promoter region of the GFAP promoter (P1 and P2) suggests that CD44-positive cells resulting from overexpression of NFIA leads to demethylation of a specific CpG on the GFAP promoter (green circles).
Nature BiotechNology accessibility (Fig. 3g, bottom) , even though our previous experiments showed robust induction of GFAP in the presence of LIF after only a short pulse of NFIA but not with LIF treatment alone. However, bisulfite sequencing of the GFAP promoter consistently highlighted one CpG in the GFAP promoter with a loss of methylation in CD44-positive cells ( Fig. 3h ) and was similarly unmethylated in astrocytes but not in LTNSCs. This CpG matches a STAT3 binding site 34 that is predicted to inhibit STAT3 binding when methylated. These data suggest that NFIA induces glial competency by multiple modes, including the regulation of chromatin accessibility and DNA demethylation.
We examined the differential gene expression programs induced by NFIA overexpression and following NFIA withdrawal in LTNSCs using RNA sequencing and the functional annotation analysis software: Database for Annotation, Visualization, and Integrated Discovery (DAVID) 35 . Hierarchical clustering of all differentially expressed genes during the time course displayed three major clusters with distinct temporal profiles ( Fig. 4a , labeled I, II and III). Cluster I includes genes associated with glial differentiation ( Supplementary Fig. 18a ). Genes associated with oligodendrocyte differentiation were absent from Cluster I. Cluster II comprises genes directly affected by NFIA expression that are rapidly lost following NFIA reduction ( Supplementary Fig. 18b ). Cluster III encompasses genes downregulated following expression of NFIA. These genes were specifically enriched for cell cycle-related processes, such as cell division, chromosome segregation, DNA repair and replication ( Fig. 4b ). NFIA triggered a negative regulation of cell cycle-specific genes (Fig. 4c ), which was reversed after NFIA removal ( Fig. 4d and Supplementary Fig. 19a ).
We studied whether functional changes in cell cycle progression were the key to acquisition of glial competency. A large proportion of cells accumulated in G1 following NFIA expression in LTNSCs (Fig. 4e ). Although expression of CCNA1 was upregulated with NFIA ( Supplementary Fig. 19b ), there was a striking decrease in CCNA1 protein and marked increase in CDKN1A (p21) (Fig. 4f ). Progressive lengthening of G1 was reported as a characteristic feature of the developing rodent cortex 36 from early embryonic (neurogenic) to later fetal (gliogenic) stages-a transition during which hPSC-derived NSCs showed progressive endogenous expression of NFIA ( Supplementary Fig. 20a ). To directly measure cell cycle lengthening, we used the FUCCI-O vector to determine the time spent by cells in G1 37 . Time-lapse analysis demonstrated that a large proportion of cells showed lengthening of the G1 phase in the (dox+) condition compared to uninduced cells (Supplementary Movies 1,x 2 and Supplementary Fig. 20b ). We also explored whether reduction of NFIA levels would result in a more moderate G1 length compatible with acquiring glial fate. Indeed, when we titrated NFIA levels by varying dox concentrations, the percentage of cells in G1 gradually decreased along with reduced dox levels, and GFAP expression was induced only at lower dox concentrations in the presence of LIF ( Supplementary Fig. 20d,e ).
To examine whether pharmacological modulation of the cell cycle in the absence of NFIA expression is sufficient to trigger the gliogenic switch, we treated cells with olomoucine (Olo), a small molecule known to lengthen G1 timing in vitro 38 . Treatment of LTNSCs with Olo increased the percentage of cells in G1 ( Supplementary  Fig. 21a ) but did not immediately activate expression of glial competency genes ( Supplementary Fig. 21b ). However, when Olo-treated LTNSCs were either maintained or induced to differentiate for an additional 12 days, we detected increased expression of glial competency genes and GFAP-positive cells ( Supplementary Fig. 21c,d) . Conversely, we knocked down FZR1(CDH1), which shortens the G1 cell cycle phase 39, 40 . Short hairpin RNA (shRNA) constructs targeting FZR1 showed efficient knockdown of the transcript (Fig. 4g) , did not affect levels of NFIA expression and decreased the percentage of cells in G1 (Fig. 4h) . Indeed, the knockdown of FZR1 partially prevented NFIA-mediated induction of CD44 and GFAP expression ( Fig. 4i,j) .
Finally, we explored the identity of candidate upstream activators of NFIA. Transforming growth factor beta (TGFβ) signaling has been implicated in timing of cell fate decisions in the spinal cord 41 and is known to modulate G1 arrest 42 . TGFβ1 treatment of neurogenic NSCs induced the expression of NFIA ( Fig. 4k ) and enrichment for cells in the G1 phase of the cell cycle ( Fig. 4l ). We treated neurogenic NSCs with TGFβ1 followed by culture in LIFcontaining medium for 2 weeks, which resulted in the appearance of GFAP+ cells (Fig. 4m) . These results indicate that TGFβ1-mediated induction of NFIA and concomitant G1 lengthening are sufficient to trigger gliogenesis. However, the resulting levels of NFIA expression, speed and efficiency did not match the results obtained with ectopic NFIA expression, suggesting that further investigation into additional extrinsic factors is required to fully substitute for forced NFIA expression.
While it has become routine to model neurodevelopmental or neurodegenerative diseases 43,44 with hPSC-derived neurons, the use of hPSC-derived astrocytes in such studies has remained limited 7, 45 . This is due, in part, to the extremely protracted onset of the gliogenic switch in humans as compared to rodent cells, which is recapitulated in vitro and makes such studies laborious, costly and inefficient. Our work presents a simple, effective strategy based on the use of a single factor to drive glial competency and astrocyte differentiation (Fig. 4n ). Our ability to combine overexpression of NFIA with patterning of early-stage NSCs enables the rapid derivation of region-specific astrocytes and will be of particular interest in studying the contribution of astrocytes to disorders affecting distinct brain regions, such as in Parkinson's disease, Alzheimer's Table 2 ). b, Gene ontology analysis of the major biological processes from each cluster represented in a. c, Global analysis of all genes and genes specifically in the cell cycle ontology (P < 0.000001 calculated using hypergeometric distribution (n = minimum of 3 biologically independent sequencing experiments). d, Graph of expression dynamics for all cell division cycle genes during the time course. e, Cell cycle analysis by FACS on NSCs with or without dox for 7 days (n = 12 biologically independent experiments). One-sided paired t-test on the G1 population with ****P < 0.0001). f, Immunoblot analysis of CCNA1 and CDKN1A in LTNSCs with or without dox for 7 days (n = 3 biologically independent experiments). g, Quantitative PCR assessing the knockdown efficiency of shFZR1 in the presence of NFIA overexpression (oneway ANOVA, ***P < 0.0004, *P < 0.0185, n = 3 biological independent experiments). h, Analysis of the cell cycle phase with or without shRNA to FZR1. One-sided paired t-test on the S phase population with P < 0.07 (ns), n = 3 biological independent experiments. i, Quantitative PCR analysis of CD44 expression in NFIA-induced cells with or without shFZR1 (one-way ANOVA, **P = 0.0055, n = 3 biological independent experiments). j, Quantitative PCR analysis of GFAP expression in NFIA-induced cells similar to I but further induced with LIF (one-way ANOVA, **P = 0.001, n = 3 biologically independent experiments). k, Immunoblot analysis of NFIA when induced with various levels of TGFβ1 for 7 days (n = 3 biologically independent experiments). l, Cell cycle analysis by FACS on NSCs treated with or without TGFβ1 for 48 h (n = 3 biologically independent experiments). One-sided paired t-test on the G1 cell cycle phase with *P = 0.0386. m, Immunofluorescence staining for NFIA and GFAP on cultures treated with or without TGFβ1 for 14 days (n = 3 biologically independent experiments). n, Immunofluorescence staining for CD44 on cultures treated with or without TGFβ1 for 16 days (n = 3 biologically independent experiments). o, Model of NFIA-induced glial competency. Scale bars, 50 μm.
Nature BiotechNology disease or amyotrophic lateral sclerosis. Such region-specific astrocytes can be further harnessed for the study of distinct trophic support, as reported for primary astrocytes derived from discrete brain regions 46,47 .
One potential concern in using NFIA to fast-forward human neural development is whether the resulting cell types match bona fide, in vivo-derived astrocytes or represent an artifactual in vitro cell type. We demonstrate faithful transcriptional identity and robust functional features of NFIA-induced astrocytes, including calcium responses to relevant stimuli that not only match but exceed the performance of primary human fetal astrocytes. In addition, we show that NFIA-induced astrocytes reliably induce maturation of hPSC-derived neurons, a functional property commonly associated with mature, adult-like astrocytes 2 . Therefore, the NFIA protocol yields astrocyte populations highly relevant for human molecular, physiological and disease-related studies.
Contrary to the role of NFIA overexpression in promoting competency for astrocyte differentiation, NFIA, when expressed at high levels, prevents further differentiation into astrocytes unless it is downregulated. We presume this is partially due to high levels of NFIA leading to G1 cell cycle arrest. It is possible that this finding explains the low efficiency of astrocyte induction in Letters Nature BiotechNology previous ectopic expression studies in the chicken spinal cord 13 , and that NFIA levels need to be carefully titrated or followed by NFIA withdrawal to achieve optimal results. NFIA null mutant mice show a near complete loss of GFAP expression in the adult brain 48 . A similar phenotype is observed in nuclear factor 1B (NFIB) mutant mice 49 . The probable redundancy of NFIA and NFIB in vivo may explain why single mutant mice do not exhibit a more severe early developmental glial specification phenotype 3 . Further exploration of the interaction among TGFβ, NFIA/B and other factors in establishing the coordinated modulation of the cell cycle that promotes glial competency during in vivo development will be of particular interest. Another intriguing finding is that transient overexpression of NFIA is not sufficient to activate an irreversible, endogenous glial competency program in the absence of STAT or BMP signal activators. These results indicate that NFIA may act in concert with other factors such as SOX9 to further stabilize the gliogenic program 50 .
Our mechanistic studies demonstrate that NFIA can rapidly trigger a chromatin state similar to that of astrocytes. The gene expression data reveal that NFIA induces transcription of a broad set of genes related to glial specification. Following release of NFIA overexpression, several genes associated with astrocyte identity remain upregulated for at least 3 days, suggesting that NFIA may open the chromatin landscape at these particular genes to poise them for activation in response to extrinsic factors. We found the NFI-motif to be highly enriched in the accessible chromatin with NFIA expression. Other highly enriched motifs, such as AP-1/JunB, require further study of their potential role ineither astrocyte differentiation or the maintenance of glial competency. The role of NFIA as a negative cell cycle regulator was recapitulated in part by pharmacological or genetic modulation of the G1 phase. The role of the cell cycle in modulating cell fate decisions in undifferentiated hPSC populations has been described previously 51 . Our data demonstrate that NFIA expression lengthens G1, and that high NFIA levels trigger G1 arrest. Further exploration of the interaction among TGFβ, NFIA and other factors in establishing the coordinated, progressive modulation of the cell cycle that promotes the glial-competent state during development will be of particular interest.
online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41587-019-0035-0. 
Letters
Nature BiotechNology
Methods Cell culture. Human pluripotent stem cells (both embryonic and induced) were maintained on vitronectin-coated dishes in Essential 8 (E8) medium (Thermo) as previously described 52 . Induced PSCs were purchased from Coriell, Patient-normal lines Nos. 41865, 41866 and patient-ALS (A4V) lines Nos 35659, 35673 and 35677. Cells were used for differentiation between passages 30-50 and passaged twice every week. Cells were subjected to mycoplasma testing every 2-3 months. Neural stem cells, LTNSCs and glial progenitors were maintained on poly-l-ornithine/laminin/fibronectin-coated dishes in NSC medium consisting of N2 media with 10 ng ml -1 Fibroblast growth factor 2 (FGF2), 10 ng ml -1 epidermal growth factor (EGF) and 1:1,000 B27 supplement. LTNSCs were used between passages 15-20 and passaged every week.
Human pluripotent stem cell-derived astrocytes were maintained on poly-l-ornithine/laminin/fibronectin-coated dishes in astrocyte media consisting of N2 medium with 10 ng ml -1 of HB-EGF (R&D Systems, No. 259-HE). After sorting, CD44-positive cells were passaged every week for 4 weeks and then every other week or until astrocyte processes started to detach.
Commercial fetal astrocytes (Sciencell) were initially maintained in a commercial medium containing serum (Sciencell). The serum-containing medium was switched to N2 with 10 ng ml -1 of HB-EGF for at least two passages before experiments were performed.
Human pluripotent stem cell-derived cortical excitatory neurons were maintained on poly-l-ornithine/laminin/fibronectin-coated dishes in neurobasal medium with brain-derived neurotrophic factor (BDNF), ascorbic acid, glial cell line-derived neurotrophic factor (GDNF) and cyclic adenosine monophosphate. More than 50% of the medium was changed every week.
Differentiation of hPSCs towards dorsal forebrain NSCs. Dorsal forebrain patterning. Human PSCs were dissociated into single cells, and 2.5-3.0 × 10 5 cells per cm 2 were plated onto Matrigel (BD Biosciences)-coated dishes in E8 containing 10 μM ROCK inhibitor (No. Y-27632). The following day (day 0), the cells were switched to Essential 6 (E6) medium containing 100 nM LDN193189 (LDN, Stemgent) and 10 μM SB431542 (SB, Tocris; LSB). The medium was changed every day for nine additional days (d8) as previously described 52 . To better promote an anterior forebrain fate (that is, for iPSCs), we added 2 μM of XAV939 (Stemgent) in addition to LSB for 3 days (d0-2) then from d3-8 maintained the cells in LSB without XAV939.
Generation of cortical rosettes/NSCs. From d8, the cells are dissociated with Accutase for 30 min at 37 °C and passed through a 40 μm cell strainer. The cells were resuspended in N2 medium with brain-derived neurotrophic factor (BDNF), ascorbic acid, Sonic Hedgehog (SHH) and fibroblast growth factor 8 (FGF8) (N2-BASF), and plated at 5 × 10 5 cells on air-dried poly-l-ornithine/laminin/ fibronectin-coated plates in 20 μl droplets. The droplets were incubated at 37 °C for 15-20 min. N2-BASF8 medium + 10 μM ROCKi medium was overlaid on the droplets and the medium changed every day. Rosette formation was expected within 2-3 days (d12).
Following rosette formation, cells were dissociated with Accutase and replated at relatively high density (3.5 × 10 5 cells per cm 2 ) to prevent spontaneous differentiation. Cultured cells were assayed for correct regional patterning, differentiated or frozen.
Neuro-ectodermal differentiation of hPSCs towards ventral spinal cord.
Similar to the dorsal forebrain, 2.5-3.0 × 10 5 cells per cm 2 were plated onto Matrigel (BD Biosciences)-coated dishes in hPSC knockout serum replacement (KSR)-based medium containing 10 μM ROCK inhibitor and 10 ng ml -1 FGF2. The following day (day 0), the cells were switched from a progressive gradient of KSR to N2 medium containing 100 nM LDN193189 and 10 μM SB431542 (LSB). The following day (day 1), the medium was switched to LSB with 1 μM of retinoic acid and 1 μM of purmorphamine and maintained for an additional 11 days (d12).
Spinal cord progenitors were dissociated with Accutase for 30 min at 37 °C and passed through a 40 μm cell strainer. The cells were then replated at 2.5 × 10 5 cells per cm 2 on poly-l-ornithine/laminin/fibronectin-coated plates and assayed for correct regional patterning, differentiated or frozen.
Derivation of LTNSCs from hPSCs.
Initially, hPSCs were differentiated using the method employed for dorsal forebrain NSCs. After initial regional patterning, differentiated cells were dissociated using 10% dispase for 10 min. Cells were then separated into clumps and resuspended in N2 medium containing 20 ng ml -1 FGF2 and cultured in sterile, non-tissue culture-treated dishes. Cells were expected to form a high number of neurospheres, and by 3-5 days neural rosette formation within the spheres should be apparent. Having purified the neurosphere cultures, they were landed on poly-l-ornithine/laminin/fibronectin-coated plates and cultured in N2 with 10 ng ml -1 FGF2, 10 ng ml -1 EGF and 1:1,000 B27 supplement (NSC media). Rosette-stage NSC outgrowth was observed to confluency and then passaged at high density (approximately 1:3) over 2-3 months. Cells maintaining neuroepithelial morphology by passage 10 in NSC media were kept and analyzed for early NSC markers and differentiation potential.
Generation of NFIA-and SOX9-inducible constructs and lentiviral production and infection. NFIA and SOX9 were cloned from cDNA using hPSC-derived astroglial progenitors (d90). FUW-tetO-GFP (Addgene, No. 30130) was digested with the restriction enzyme EcoRI to remove the GFP fragment, and either NFIA or SOX9 was inserted using traditional ligation cloning. Plasmids containing NFIA, SOX9, FUCCI-O or M2-rtTA (Addgene, No. 20342), the packaging vector psPAX2 (Addgene, No. 12260) and the envelope pMD2.G (Addgene, No. 12259) were transfected into 293 T cells X-tremeGene HP (Sigma) at a molar ratio of 1:2:1. Virus was harvested at 48 and 72 h post-transfection and concentrated using AMICON Ultra-15 Centrifugal Filter Units (Millipore). NSCs were plated at 3.5 × 10 5 cells per cm 2 on poly-l-ornithine/laminin/fibronectin-coated dishes. The cells were incubated with viral particles generated (as described above) for 16-20 h. The medium was then switched to NSC medium with 1-2 μg ml -1 doxycycline and daily medium change for a minimum of 5 days. Cells were then detached using 0.05% trypsin and washed several times in preparation for CD44 labeling.
Intracellular FACS analysis and sorting. For both live and fixed sorting, cells were dissociated using 0.05% trypsin and washed twice with phosphate buffered saline (PBS).
Fixed GFAP and CD44 analysis. Using the BD Cytofix/Cyto Perm kit (BD), 1 × 10 6 cells were resuspended in 1 ml Cytofix and placed on ice for 1 h. The cells were then washed twice with 1× Cyto Perm Buffer and resuspended in 100 μl of 1× Cyto Perm Buffer. Alexa 647-conjugated CD44 (Biolegend) and unconjugated GFAP (Dako) were added to the cells, as described by the manufacturer, and incubated for 40 min on ice. The cells were then washed twice with 1× Cyto Perm Buffer and resuspended in 100 μl of 1× Cyto Perm Buffer for secondary labeling. For labeling of GFAP, Alexa 488 or 555 was added to the cells for 30 min on ice. Cells were washed twice with 1× Cyto Perm Buffer and submitted for analysis.
Live CD44 sorting. Approximately 4-5 × 10 6 cells were resuspended in 100 μl of sort buffer (2% fetal bovine serum, 1 mM EDTA in PBS), and CD44 conjugated with Alexa 647 was incubated, as per the manufacturer's instructions, on ice for 20-30 min. Cells were washed twice with sort buffer and submitted to the sorter. CD44-positive cells were maintained in astrocyte induction medium (N2 with 10 ng ml -1 heparin-bound EGF (R&D Systems) and 10 ng ml -1 leukemia inhibitory factor (Peprotech) without doxycycline.
Immunohistochemistry. Cells were fixed in PBS containing 4% paraformaldehyde for 10 min, permeabilized using PBS with 0.5% Triton-X for 5 min and stored in PBS with 0.2% Tween-20. The blocking solution contained 5% donkey serum in PBS with 0.2% Tween-20. Primary antibodies were diluted in the blocking solution and typically incubated overnight at 4 C. Secondary antibodies conjugated to either Alexa 488, Alexa 555 or Alexa 647 (Thermo) were added to the cells with incubation for 30 min. Nuclei were identified by staining the cells with 4′,6-diamidino-2-phenylindole (DAPI, Thermo). A list of antibodies used in this study is given in Supplementary Table 3 .
Immunoblot. Cells were harvested and lysed with RIPA buffer, and protein was quantified using Precision Red (Cytoskeleton, Inc). Ten micrograms of protein was loaded to analyze protein expression. Full scans of blots for Fig. 2b (Supplementary  Fig. 22 ), Fig. 4f (Supplementary Fig. 23 ), Fig. 4k (Supplementary Fig. 24 ) and Supplementary Fig. 7c (Supplementary Fig. 25 ) are available.
Gene expression and ATAC-sequencing analysis. RNA sequencing. RNA was isolated as previously described. Total RNA was submitted to the Memorial Sloan Kettering Cancer Center (MSKCC) Genomics Core for paired-end sequencing, aiming for 30-40 million reads. Raw FASTQ files were trimmed for adapters and aligned to the ENSEMBL GRCh38 genome build using STAR 2.5.0. Matrices were generated from the aligned files using HTSeq 53 and imported into DESeq2 54 for further analysis using a standard pipeline. A list of the normalized read counts represented in Fig. 1 and Supplementary Fig. 8 can be found in Supplementary  Table 1 , and a list of genes expressed from all samples in Fig. 4 can be found in Supplementary Table 2 .
ATAC sequencing. Raw FASTQ files were aligned to the hg19 genome build using Bowtie2 55 . Comparative analysis of alignment files was performed using the deepTools software package 56 . Motif analysis and peak annotation were performed using HOMER software 57 and visualized using the IGV browser 58 .
All FASTQ files and Supplementary files were uploaded to National Center for Biotechnology Information Gene Expression Omnibus under accession code GSE104232.
Cytokine treatment of human astrocytes. Astrocytes were plated at 2 × 10 4 cells per cm 2 and treated with 3 ng ml -1 IL-1α (Sigma), 30 ng ml -1 tumor necrosis factor (Cell Signaling Tech) and 400 ng ml -1 C1q (MyBioSource) for 24 h. The medium was isolated and spun down to remove debris, and C3 levels were measured using the Human Complement C3 ELISA Kit (Abcam) as per the manufacturer's instructions. A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code
Data collection
External RNA sequencing data was downloaded using the SRA Toolkit (NCBI).
Data analysis
ATAC-Seq analysis was performed following the workflow: https://www.encodeproject.org/atac-seq/ which was aligned to hg38 and uses MACS (v2.2.1) and HOMER (v4.9.1) software for peak and motif identification. The IGV browser (v2.3.97) was used to visualize peak locations.
RNA-Seq analysis was performed following the workflow: https://www.bioconductor.org/help/workflows/rnaseqGene/ which was aligned to hg38 and uses Bowtie2 (v2.2.5) for alignment, HTSeq (v0.6.1p1) for generation of a counts table and DESeq2 (v1.20.0) for differential gene expression analysis. The IGV browser (v2.3.97) was used to visualize RNA sequencing mapping.
The Imaris software was used to identify overlap of pre and post synaptic proteins using signal thresholding.
FIJI/ImageJ (v2.0.0-rc-68) was used to analyze and quantify the calcium imaging as well as analysis of the FUCCI-O timelapse movies.
Flowjo (v10.4) software was used to gate and quantify the number of cells.
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For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability Data generated during this study is deposited at NCBI GEO (Both ATAC-seq and RNA-seq) under accession number GSE104232.
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Sample size
A minimum of 3 independent biological replicates were analyzed for the study. The choice of 3 was the minimum in terms of reproducibility and manageable within the time frame. We believe the sample size was sufficient as our experiments were highly reproducible within those 3 experiments.
Data exclusions hPSC differentiations where cultures did not meet the expected identity were discarded. Samples that resulted in poor RNA or protein quality were discarded. Although the exclusions were not pre-established, our goal was to trigger the gliogenic switch in neural stem cells as well as other regionally distinct neural stem cell populations. If we could not generate them for any particular reason, these differentiations would not be able to address our main question. Technically, if we could not isolate good quality and quantity of RNA or protein we could not extract information from these samples.
Replication
Aside from technical issues, the findings for NFIA-induced experiments were reproducible through a minimum of 3 biological replicates in LTNSCs. Astrocytes generated from NFIA were replicated and extended to other pluripotent stem cell lines (both ES and iPS).
Randomization Experiments were not randomized however additional members of the laboratory have performed independent experiments using this method and have successfully generated astrocytes.
Blinding
Experiments were not blinded because we sought to investigate the role of NFIA in triggering glial competency and the results were clear where neural stem cells exposed to NFIA lead to astrocyte differentiation versus neural stem cells not exposed remain as stem cells or becomes neurons.
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